2326 GMT - The threat of U.S. tariffs could see protective-garment manufacturer Ansell face the re-emergence of uneven demand due to customer destocking, UBS analysts write in a note. They tell clients that they have become more optimistic about full-year sales growth at Ansell's healthcare unit, but that there are some risks ahead. They highlight the possibility that customers have built up inventory ahead of potential tariffs, which would eventually hit demand as they then use up the stock. Ansell needs to deliver on first-half analyst earnings expectations to continue recent support for its stock, the UBS note adds. UBS lifts its target price 12.5% to A$36.00 and keeps a buy rating on the stock, which is up 0.4% at A$30.63. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

January 28, 2025 18:27 ET (23:27 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.